Article
ATM aberrations in chronic lymphocytic leukemia: del(11q) rather than ATM mutations is an adverse-prognostic biomarker.
Leukemia - 1 Jul 2025
Thorvaldsdottir Birna, Mansouri Larry, Sutton Lesley-Ann, Nadeu Ferran, Meggendorfer Manja, Parker Helen, Brieghel Christian, Laidou Stamatia, Moia Riccardo, Rossi Davide, Kotaskova Jana, Delgado Julio, Rodríguez-Vicente Ana E, Benito Rocío, Rigolin Gian Matteo, Bonfiglio Silvia, Scarfò Lydia, Mattsson Mattias, Davis Zadie, Baliakas Panagiotis, Rapado Inmaculada, Miras Fatima, Martinez-Lopez Joaquín, de la Serna Javier, Hernández Rivas Jesús María, Larráyoz María José, Calasanz María José, Smedby Karin E, Espinet Blanca, Puiggros Anna, Bullinger Lars, Bosch Francesc, Tazón-Vega Bárbara, Baran-Marszak Fanny, Oscier David, Nguyen-Khac Florence, Zenz Thorsten, Terol Maria Jose, Cuneo Antonio, Hernández-Sánchez María, Pospisilova Sarka, Gaidano Gianluca, Niemann Carsten U, Campo Elias, Strefford Jonathan C, Ghia Paolo, Stamatopoulos Kostas, Rosenquist Richard
Abstract excerpt
Despite the well-established adverse impact of del(11q) in chronic lymphocytic leukemia (CLL), the prognostic significance of somatic ATM mutations remains uncertain. We evaluated the effects of ATM aberrations (del(11q) and/or ATM mutations) on time-to-first-treatment (TTFT) in 3631 untreated patients with CLL, in the context of IGHV gene mutational status and mutations in nine CLL-related genes. ATM mutations...
Read the complete abstract on PubMed